OKYO Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd., a foreign private issuer, furnished a Form 6-K dated July 28, 2023. The report concerns the company’s continued listing on the Nasdaq Capital Market.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating performance metrics.
Material Change Versus Prior Period
Nasdaq notified OKYO that its ordinary shares had closed below the required minimum market value of $35 million for 30 consecutive business days. This resulted in a deficiency under Nasdaq Listing Rule 5550(b)(2), the Market Value Rule.
Outlook, Risks, and Unusual Items
- The deficiency places the company’s continued Nasdaq Capital Market listing at risk.
- The filing text does not provide a deadline, remediation plan, appeal status, or outcome.
- No financial guidance or management outlook is included.
- The announcement was furnished as Exhibit 99.1 and is not deemed filed for purposes of Section 18 of the Securities Exchange Act, nor incorporated by reference into other filings unless expressly stated.
Investor Verification Points
- Verify the applicable Nasdaq cure period and any subsequent compliance or delisting notices.
- Review whether OKYO pursued measures to restore compliance with the $35 million market value requirement.
- Assess the potential impact of continued noncompliance on trading liquidity and the company’s access to capital markets.
- Review Exhibit 99.1 and subsequent SEC filings for additional details.